Compare GSK plc (GSK) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kyndryl Holdings Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Kyndryl Holdings Inc trades at $13.43 (market cap $2.91B). The key difference: GSK plc is far larger — about 35.3× Kyndryl Holdings Inc's market cap, and GSK plc pays a 3.57% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| GSK | KD | |
|---|---|---|
Market Cap | $102.60B | $2.91B |
Sector | Health | Technology |
52-Week High | $61.18 | $33.14 |
52-Week Low | $38.22 | $10.59 |
Enterprise Value | $123.04B | $5.74B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Kyndryl (KD) trades at $13.025, down 4.44% on the day, with a neutral technical signal. The company reported a net loss in Q1 2027, missing revenue estimates, but maintains a strong cash flow position with $942M from operations in 2025. Recent news highlights strategic acquisitions and AI service expansions, while an ongoing legal investigation introduces uncertainty. The stock's valuation shows a high P/E of 36.11 but attractive EV/EBITDA of 4.04, with analyst consensus leaning hold.
The outlook is mixed: positive cash flow and strategic moves in AI modernization offer growth potential, but recent earnings misses and legal scrutiny pose risks. Investors should weigh the company's turnaround progress against execution challenges and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
